Innoviva Inc
$ 23.76
-1.82%
10 Apr - close price
- Market Cap 1,806,191,000 USD
- Current Price $ 23.76
- High / Low $ 24.41 / 23.51
- Stock P/E 7.16
- Book Value 15.71
- EPS 3.38
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.29 %
- 52 Week High 25.14
- 52 Week Low 16.52
About
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Analyst Target Price
$33.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-02-29 | 2023-11-01 | 2023-08-02 | 2023-05-09 |
| Reported EPS | 1.944 | 0.3846 | 0.77 | -0.7429 | 0.26 | 0.12 | -0.55 | 0.46 | 0.76 | 0.98 | 0.02 | 0.42 |
| Estimated EPS | 0.574 | 0.4 | 0.5 | 0.33 | 0.41 | 0.27 | 0.24 | 0.17 | 0.23 | 0.27 | 0.26 | 0.23 |
| Surprise | 1.37 | -0.0154 | 0.27 | -1.0729 | -0.15 | -0.15 | -0.79 | 0.29 | 0.53 | 0.71 | -0.24 | 0.19 |
| Surprise Percentage | 238.676% | -3.85% | 54% | -325.1212% | -36.5854% | -55.5556% | -329.1667% | 170.5882% | 230.4348% | 262.963% | -92.3077% | 82.6087% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.43 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None |
| Amount | $0.25 | $0.25 | $0.25 | $0.25 | $0.25 | $5.571428571 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INVA
2026-04-10 20:26:00
This article from Stock Traders Daily analyzes Innoviva Inc. (NASDAQ: INVA), highlighting strong sentiment across all horizons and an exceptional risk-reward short setup. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis indicating strong support and resistance levels for the stock.
2026-04-08 12:12:11
Cantor Fitzgerald has reiterated an Overweight rating and $32.00 price target for Innoviva Inc. (NASDAQ:INVA), highlighting the company's strong foundational stability driven by its recurring royalty business, which generated approximately $250 million in 2025. The firm noted Innoviva's impressive financial health with a 75% gross profit margin and a 14.64 current ratio, along with aggressive capital redeployment into its Innoviva Specialty Therapeutics segment and strategic investments. BTIG also initiated coverage with a Buy rating and a $35.00 price target, anticipating significant benefits from royalty rights for COPD and asthma therapies through 2030.
2026-04-07 07:18:00
Shares of Innoviva, Inc. (NASDAQ:INVA) have crossed above their 200-day moving average, indicating a potential bullish trend. This surge is attributed to positive analyst sentiment and the company's stable, royalty-focused business model in the biotech sector. Analysts maintain a 'Moderate Buy' rating with an average price target of $34.80, suggesting further upside potential for the stock.
2026-04-04 16:41:05
This article provides an earnings analysis and prediction for INVA, detailing past quarterly results and future estimates. It highlights that analysts project Q1 2026 revenue of $100.31M and an EPS of $0.39, with recent estimates showing no change. The report also examines how INVA's stock price typically reacts to earnings announcements, noting a 0.99% change 10 days before and a 3.2% change 10 days after, suggesting potential buying opportunities based on long-term fundamentals.
2026-04-03 19:39:07
This page provides comprehensive financial information for Innoviva Inc (HVE.SG), including its current stock price, recent news, quotes, and historical data. As of April 2, 2026, the stock was trading at 19.80 EUR, down 1.98%. The page also details performance metrics compared to the S&P 500, showing Innoviva's YTD return at +20.73% and 1-year return at +20.73%.
2026-04-03 12:41:05
This article provides a comprehensive overview of Innoviva, Inc. (INVA), a biopharmaceutical company, including its stock price, historical data, and financial performance. It details the company's royalty portfolio of medicines, development pipeline, key financial metrics like market cap and P/E ratio, and analyst insights. The report also lists comparable companies in the biotechnology sector.
